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Immunity is one of homeostatic mechanisms of the living body, which can exclude 
the foreign things different from oneself. In vertebrate, the immune system is divided 
into innate immunity and acquired immunity. Protection of body with the innate 
immune system is nonspecific and provides comprehensive responses to pathogens; on 
the other hand, the acquired immune system causes a stronger and specific immune 
response, which discriminates and memorizes foreign antigens. Both innate and 
acquired immunity depend on the ability of immune system to distinguish between self 
and non-self molecules.  
Immunoglobulins play important roles in antigen recognition during the acquired 
immune response, and the complementarity-determining region (CDR) 3 of the heavy 
chain is considered as the critical antigen-binding site. There are enormous complexities 
in the antigen recognition of antibody repertoire, which hampered the explicit 
understanding of antibody system. Previously a statistical protocol for the extensive 
analysis of heavy chain variable region repertoires and the dynamics of their immune 
response using next-generation sequencing (NGS) was developed. In addition, the 
properties of important antibody heavy chains predicted in silico by the protocol were 
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examined by gene synthesis and antibody protein expression; however, the 
corresponding light chain that matches with the heavy chain could not be predicted by 
our protocol. To understand the dynamics of heavy chain and light chain pairing, I 
firstly tried to obtain an artificial light chain that pairs with a broad range of heavy 
chains and then analyzed its effect on the antigen binding of heavy chains upon pairing.  
During the pre-B cell stage, the surrogate light chain (SLC) could pair with the 
nascent immunoglobulin µ heavy chains (Ig-µH) and promote them to function in the 
periphery. On the basis of this property, I designed several versions of genetically 
engineered “common light chain” prototypes by modifying the SLC structure. Among 
them, the mouse-derived VpreB1λ5Cκ light chain showed acceptable matching property 
with several different heavy chains without losing specificity of the original heavy 
chains, though the antigen affinities were variable. I found that the extent of matching 
depended on the heavy chain; the conventional IgLs, Vκ_2ORB and Vκ_2A6I, 
considerably maintained the antigen binding of IGHV9-3 heavy chain but not of 
IGHV1-72 heavy chain. Thus, the antigen recognition of the heavy chain is variably 
affected by the paired light chain, and that the artificial light chain, Mm_VpreB1λ5Cκ, 
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maintained the antigen binding of either heavy chain, indicating its potential to be a 
“common light chain”. These results provide an initiative observation on the correlation 
of antibody heavy and light chain structures, and also provide a novel system to analyze 
the effects of light chains pairing in antigen recognition of heavy chains. 
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General Introduction 
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The immune system is a mechanism that protects living organisms from disease by 
identifying and killing abnormal substances such as pathogens and cancer cells in the 
body. This mechanism can sense a variety of pathogens and distinguish pathogens from 
their own healthy cells and tissues in order to function properly. 
In vertebrate, the immune system includes innate immunity and acquired immunity. 
Innate immunity does not respond to various pathogens separately but always in “a state 
of war”, so the time to activate the efficacy is short. Acquired immunity is achieved by 
cellular immunity of functional cells such as lymphocytes, and humoral immunity of 
blood proteins such as antibodies and complement. Lymphocytes include T cells and B 
cells. B cells can differentiate and mature to produce immunoglobulins. In addition, 
dendritic cells that take up and degrade antigens by phagocytosis and present antigens to 
T cells are also involved in immune functions. These cells are transported to bone 
marrow and interact with lymphoid tissues such as the thymus, lymph nodes and spleen 
to function effectively (Alberts et al., 2002).  
Antibody, also known as immunoglobulin, contains four heterologous polypeptide 
chains. The two chains with larger molecular weight are called heavy chain, and the two 
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chains with smaller molecular weight are called light chain. The amino acid 
composition of two H chains and two L chains in the same Ig molecule is identical 
(Janeway et al., 2001). 
The structure of antibodies consists of variable regions and constant regions. The 
variable regions play important roles in antigen recognition. The variable regions of 
immuoglobulin heavy chains (IgHs) show enormous diversity by V-D-J gene 
rearrangements that include random nucleotide additions in the 
complementarity-determining region (CDR) 3 (Tonegawa, 1983; Xu, Davis et al., 2000). 
The variable regions of immunoglobulin light chains (IgLs) are less diverse than IgHs 
because of the lack of DL gene segments and poor nucleotide insertions (Jackson et al., 
2013). 
  The use of next-generation sequencing (NGS) to analyze antibody repertoires is 
advantageous for rapid and extensive identification of antigen-specific antibodies 
(DeKosky et al., 2015; Georgiou et al., 2006; Weinstein et al., 2009). Previously a 
method for the holistic analysis of IgH and IgL repertoires respectively from mice and 
humans was reported (Kono et al., 2017; Sun et al., 2019). In contrast to the recent 
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single cell-based NGS repertoire analysis (Marcus et al., 2006; Dash et al., 2011), this 
method has an advantage of easy and inexpensive handling of huge numbers of IgH and 
IgL sequences, but has a disadvantage of inability to determine the pairing of IgH and 
IgL. 
  In addition, I developed an intelligible method for detecting antigen-responding IgH 
repertoires by analyzing dynamic changes in whole antibodies in individual mice during 
4-hydroxy-3-nitrophenyl acetyl (NP) hapten and chicken γ-globulin (CGG) antigen 
immunization and found that the major responding IgHs were 
IGHV1-72/IGHD1-1/IGHJ2 for NP-hapten and IGHV9-3/IGHD3-1/IGHJ2 for 
CGG-carrier protein. The former antigen-antibody interaction was extensively analyzed 
by the crystallography (Mizutani et al., 1995), whereas the latter interaction was a new 
finding. I confirmed the latter interaction by gene synthesis of NGS reads and antibody 
protein expression followed by ELISA test. During the course of the study, I realized 
the lack of information on the mode of interaction between IgH and IgL, and the effect 
of IgL pairing on the antigen binding affinity of IgH.  
  In this report, I described examples of IgH/IgL matching in terms of the antigen 
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binding of IgHs specific to NP-hapten and CGG-carrier antigens. In addition, we 
attempted the construction of “common light chain” models that preserve the potential 
to associate with a wide variety of IgHs.  
  During the early stage of B cell development, the V-D-J rearranged µH pairs with the 
surrogate light chains (SLCs), VpreB and λ5, to form the pre-B cell receptor (pre-BCR) 
(Tsubata et al., 1990; Karasuyama et al., 1990). Pre-BCR serves as an important 
checkpoint and participates in IgH repertoire selection, which is crucial for B cell 
maturation and migration to the periphery (Mårtensson et al., 2010; Melchers 2015; Sun 
et al., 2018). These findings suggest that the SLC can bind to various IgHs and select 
them to function in the peripheral immune system (Boekel et al., 1997). Based on this, I 
utilized SLC molecules to construct “common light chain” models, and examined their 
matching ability to various IgHs and their effect on antigen binding affinities of IgHs in 
comparison to those of conventional IgL. These results would provide useful 
information on antigen recognition of IgH/IgL pairs and on the optimization of antibody 
drugs. 
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Chapter 1 
 
Construction of VpreBλ5Cκ light chains as “common light chain” models 
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Introduction 
To recognize and resist the different kinds of pathogens, antibody diversity is very 
important. A huge number of about 1015 different antibodies can be produced after 
immunization. This diversity comes from the gene rearrangements, N and P genes 
insertion, inherent mutagenesis and combination of IgH and IgL.  
  The CDR3 of IgH is variable and is considered as the most critical antigen-binding 
site. It has been estimated that the gene rearrangement can result in up to a huge 
diversity of more than 1010 different variations of CDR-H3. It’s a “black box” so far. 
Recently, the advent of NGS methods made it possible to analyze the diversity. 
Previously a method for holistic analysis of the immunoglobulin heavy chain (IgH) 
and light chain (IgL) repertoires respectively from mouse was reported, but it did not 
determine the pairing of IgH and IgL sequences in that study (Kono, Sun et al. 2017). 
Comprehensive analysis of heavy chain repertoire by next generation sequencing (NGS) 
was established as follows. Mice were immunized with antigens. After 2 weeks, the 
spleen was collected and cDNA of antibody IgHs was used as the template, the 
universal adapter was ligated to 5’ end as the forward primer, and at the 3’ end, the 
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sequences of IgH constant region1 were used as the reverse primer. After sequencing, 
the heavy chain variable region gene sequences (about 100 k reads) could be obtained. 
This method has an advantage in easy and inexpensive handling of huge numbers of 
IgH or IgL sequences but has a disadvantage of inability to determine the pairing of IgH 
and IgL. 
The whole antibody repertoire could be visualized using the three dimensional plots 
of VDJ genes with 110 IGHV genes, 12 IGHD genes, and 4 IGHJ genes. Thus, It 
became possible to comprehensively analyze the antibody repertoire in individuals 
(Kono et al., 2017). 
During the antibody expression, secreted nascent heavy chain has to combine with a 
light chain in the endoplasmic reticulum before detachment from the heavy 
chain-binding protein (Bole et al., 1986). Therefore, for the expression of the 
antigen-specific heavy chains detected, analysis of the paired IgH/IgL repertoires has 
great significance.  
  Previously, research has been conducted on detection of the natural pairing of 
antibodies (Meijer et al., 2006). In recent years, using single-cell genome sequencing 
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(Marcus et al., 2006; Dash et al., 2011), emulsion-based technology was developed for 
in-depth analysis of paired VH-VL repertoires in large numbers of B cells (>2 × 106 per 
experiment) (DeKosky et al., 2015). In addition, a frequency-based pairing algorithm 
for T cell receptor (TCR) pairing was obtained, which accounts for allelic inclusion and 
sequencing errors (Lee et al., 2017). The light chains (TCRα) have relatively low 
genetic diversity and might be shared to more than one heavy chain (TCRβ) (Lee et al., 
2017; Jackson et al., 2012; Hoi et al., 2013). Thus, these methods might be required for 
further screening for the most matching IgH/IgL (TCRα/ TCRβ) pairs. 
  During the early stages of B cell development, rearranged μH pairing with the 
surrogate light chain (SLC), consisting of VpreB and λ5, forms the pre-B cell receptor 
(pre-BCR) (Tsubata and Reth, 1990; Karasuyama et al., 1990). Pre-BCR serves as an 
important checkpoint and the SLC participates in IgH repertoire selection, which is 
crucial for B cell survival (Mårtensson et al., 2010; Melchers, 2015; Sun et al., 2018). 
These findings suggest that the SLC can bind to various matured heavy chains 
expressed on the B cell surface.  
  Previous research on paired heavy- and light-chain antibody repertoires has shown 
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that the public CDR-L3 genes generally have low frequency of nucleotide insertions at 
VJ junctions, which are closer to the germ line. SLCs do not have nucleotide insertions 
and lack mutations, consistent with the characteristics of common light chains 
(DeKosky et al., 2015). In addition, the similar CDR regions in conventional light chain 
sequences can also be found in the SLC sequences (Ohnishi and Melchers, 2003). 
  In the current study, using the SLC sequences, I constructed a “common light chain” 
to resolve the issues regarding the antigen-specific heavy chains lacking matching light 
chains detected in our previous study and provided a new approach for analyzing the 
pairing of light and heavy chains. 
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Materials and Methods 
Construction of VpreBλ5Cκ  light chains 
  On the basis of the SLC structures, the engineered VpreBλ5Cκ light chains were 
constructed by the following processes: 1. the “tail” domain of λ5 was cut; 2. the 
redundant non-Ig part of VpreB was cut and removed; 3. the terminal of VpreB and the 
“tail” of λ5 were spliced to form a new CDR-L3 loop; 4. the Arg101Tyr mutation was 
introduced into VpreB; 5. the engineered VpreB-λ5 light chain variable region 
(VpreBλ5) was connected to the human Igκ constant region (Cκ) already present in the 
antibody expression vector (Mammalian PowerExpress System, TOYOBO MPH-101). 
 
Cell culture 
Before and after transfection, CHO-S cells were maintained in Dulbecco's Modified 
Eagle’s Medium (D-MEM, Wako) medium supplemented with 10% fetal bovine serum 
(Cell Culture Biosciences), 1% MEM Non-Essential Amino Acids, 1% Pen Strep, 2 
mM L-glutamine, and 1 mM sodium pyruvate (all from GIBCO) and rested in a 
humidified 37°C incubator. 
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DNA plasmids and antibody gene syntheses 
  The synthesized genes in the pTAKN vector (Eurofins) were inserted into an 
antibody-expression vector (Mammalian Power Express System, TOYOBO) containing 
the human-derived Igγ1 heavy chain constant region gene and the Igκ light chain 
constant region gene. All the DNA plasmids were expanded in TOP10 Chemically 
Competent Escherichia coli (Invitrogen) and purified with the QIAprep Spin Miniprep 
or Midi/Maxprep Kit (Qiagen) according to the manufacturer’s instructions.  
The heavy-chain variable region genes synthesized were inserted into the 
pEHgammaX1.1 (TOYOBO) vector using the BsiWI and NheI sites. The light-chain 
variable genes synthesized were inserted into the pELkappaX2.2 (TOYOBO) vector 
using the BsiWI and MluII sites. The heavy chain and light chain expression vectors 
were ligated with the Quick Ligase Kit (New England BioLabs) to construct intact 
antibody expression vectors.  
 
Transfection and antibody protein expression 
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5 µL of DNA (0.5 µg/mL) and 6.25 µL Lipofectamine LTX (Invitrogen) were 
incubated in 500 µL Opti-MEM I Reduced Serum Medium (GIBCO). After incubation 
for 25 min at room temperature (25°C), all of the medium was added to the 
pre-prepared 6-well cell culture dishes containing about 70% CHO-S cells in 2 mL of 
CHO medium lacking penicillin-streptomycin and incubated for 4 h at 37°C. Then, the 
antibiotic-free medium was changed to the medium containing penicillin-streptomycin 
and incubated at 37°C overnight. After 24 h, 20 µg/mL puromycin was added for cell 
selection. The stably transfected cell colony was obtained approximately 7 days later, 
and the supernatant was collected after 2 weeks. 
 
Immunoassays  
The antibody concentration of the supernatant samples was adjusted to the same level 
as follows. Ninety-six well Maxisorp Nunc-Immuno plates (Thermo) were coated with 
unconjugated anti-human IgG polyclonal antibody (Dako) at 1:500 dilution in coating 
buffer (50 mM sodium carbonate-bicarbonate buffer, pH 9.6) and incubated at 4°C 
overnight. Then, 1% bovine serum albumin (BSA, Sigma) in phosphate-buffered saline 
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(PBS, Sigma) was used for blocking at room temperature (RT, 25°C) for 1 h. Standard 
curves were constructed using a purified influenza-specific human IgG recombinant 
antibody (National Institute of Infectious Diseases, Japan) at serial dilutions ranging 
from 12.5 to 800 ng/mL in wash buffer (PBS containing 0.05% Tween-20) at RT for 2 h. 
Then, the plates were further incubated with horseradish peroxidase (HRP)-conjugated 
anti-human IgG antibody (Dako) at RT for 1 h. Color development was performed with 
o-Phenylenediamine dihydrochloride (OPD, Sigma) buffer (0.05 M citrate-PO4 buffer, 
pH 5.0) containing 0.4 mg/mL OPD and 0.04% v/v 30% H2O2. The absorbance was 
measured at 490 nm. When the concentration of the reference was between 25 and 400 
ng/mL (50 and 800 ng/mL), a linear relationship was obtained between absorbance and 
concentration in the fitted curve, with R2 > 0.97.  
To determine the binding capacity of antibody samples (Fig. 10, Fig. 16B and Fig. 
17), the supernatants were diluted in wash buffer, and the antibody concentration was 
adjusted to 10 µg/mL. NP-BSA and CGG antigens were coated in coating buffer at a 
concentration of 10 µg/mL and incubated at 4°C overnight. After blocking, cell culture 
supernatants were added to each well. After 1 h of incubation at RT, the plates were 
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incubated with HRP-conjugated anti-human IgG (H+L) antibody (Jackson 
ImmunoResearch) at 25°C for 1 h. The binding activities of the antibodies are expressed 
in terms of O.D. 450 nm. 
 
In silico simulation 
  All the steps for homology modeling and ligand docking were performed using the 
Molecular Operating Environment (MOE) software. The crystal structure of the 
conventional light chain (PDB: 1NGP) was chosen as the template for homology 
modeling. The intermediate structures were obtained by induced-fit homology modeling 
using the reaction-field electrostatics and the Amber12: EHT force field parameters, 
which are suitable for both protein and small molecules (AmberTools 12 Reference 
Manual, 2015; Hoffmann, 1963). The generalized Born/volume integral (GB/VI) 
method was used for the model scoring (Labute, 2008). The protonation was performed 
before refining the final model by using Protonate3D in the MOE software (Labute, 
2014). The final models were further refined by gradient minimization until the RMS 
gradient was lower than 0.05 kcal mol-1 Å-1. 
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  The final models were docked with the NPA molecule from the crystal structure 
(1NGP) in Protein Data Bank using default settings. Briefly, the Triangle Matcher was 
used for placement, the Rigid Receptor was used for refinement, the London dG was 
used for initial scoring, and the GBVI/WSA dG was used for final scoring (Gentile et 
al., 2015). 
The final structures were checked with PROCHECK (Laskowski et al., 1993), and 
the interaction patterns between receptors and ligands were analyzed with the MOE 
software. The residue scans were also performed for the heat stability analysis of the 
mutations using MOE. 
 
Gene classification 
  Phylogenetic tree was used for gene classification. The tree was generated using the 
neighbor-joining (NJ) algorithm with the MEGA7 software by analyzing the protein 
sequences. 
   
Statistical analysis 
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Statistical analysis was performed in Microsoft Excel. The error bars on the figures 
indicate the standard deviation from the mean. Student’s t-test was used to evaluate the 
significances of differences between experimental data. 
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Results 
Concept of the “common light chain” 
  The rearrangement of IgH genes occurs before that of IgL genes, where the surrogate 
light chain (SLC) is associated with nascent IgH instead of IgL (Fig. 1). Here, sequence 
alignments were performed between SLC (the sequences from PDB: 2H32) and 
conventional λ1 light chain (the sequence from PDB: 3PIQ). The region similar to 
CDR3 in the SLC was composed of a portion of VpreB and λ5 close to the non-Ig 
region (Ohnishi and Melchers, 2003) (Fig. 2). As shown in Fig. 3, I modified the 
different SLCs to form the VpreBλ5 light chains. Based on the SLC structures, the 
engineered VpreBλ5Cκ light chains were constructed by the following processes: 1. Cut 
the “tail” domain of λ5; 2. Cut and remove the redundant non-Ig part of VpreB; 3. 
Splice the terminal of VpreB and the “tail” of λ5 to form a new CDR-L3 loop; 4. 
Introduce the mutation of Arg101Tyr in VpreB; 5. Connect the engineered VpreB-λ5 
light chain variable region (VpreBλ5) to the human Igκ constant region (Cκ) that was 
already present in the antibody expression vector. 
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Difference between species of SLC sequences 
  Different VpreB and λ5 genes from different species were compared and classified 
(Fig. 4 and Fig. 5). The sequence similarity and identity were analyzed. The regions 
corresponding to CDR-L3 in VpreB and λ5showed the significant differences. Because 
the SLC gene sequences differ among various species, both human and mouse-derived 
VpreB1λ5 light chains (Hs_VpreB1λ5 and Mm_VpreB1λ5) were designed (Fig. 4). It 
showed that VpreB1 and VpreB2 sequences were quite similar, however VpreB3 
sequences were different. At an early phase of assembly, Ig-µH also associates with 
VpreB3 and λ5 (Shimizu et al., 2002, Ohnishi and Takemori, 1994). I compared the 
gene sequences between human-derived VpreB1 and VpreB3 and synthesized the 
Hs_VpreB3λ5 light chain gene (Fig. 5). 
 
Construction of antigen-antibody complex in silico 
  In order to assess the antigen bindings of NP-specific IgHs paired with each light 
chain models (Mm_λ1Cκ, Mm_VpreB1λ5Cκ, and Hs_VpreB1λ5Cκ), in silico docking 
simulations were performed. The crystal structure 1NGP was as the control, which is 
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the original structure of IGHV1-72/Mm_λ1 antibody. Through the comparison of 
protein sequences of IgHs and IgLs from different antibodies, I found that the similarity 
of IgHs and IgLs compared to the sequences from 1NGP were more than 30% (Fig. 6A). 
Thus, the 1NGP structure was used as the template for homology modeling and the final 
structures were evaluated using Ramachandran plot (Phi-Psi plot), more than 98% 
residues fall within the allowed ranges (Fig. 6B). The antigen-antibody complexes 
containing the small molecule antigen (NP) were constructed using docking simulation. 
 
Effect of the Arg in the middle of the CDR-L3  
In the previous studies, the most significant IgH repertoires were found to be 
NP-specific IGHV1-72 (short for IGHV1-72/IGHD1-1/IGHJ2) and CGG-specific 
IGHV9-3 (short for IGHV9-3/IGHD1-1/IGHJ2) (Kono, Sun et al. 2017). To make it 
consistent with the λ1 light chain already known to pair with IGHV1-72 (Mizutani et al., 
1995), the positively charged arginine (Arg) in the middle of the new CDR-L3 of 
VpreB1λ5Cκ was replaced with a tyrosine (Tyr) carrying no charge (R101Y, RtY) (Fig. 
3 and Fig. 4). Upon introducing in silico mutations of R101Y in Mm_VpreB1λ5Cκ and 
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Hs_VpreB1λ5Cκ, I found that the Arg residues in the middle of CDR-L3 in both 
Mm_VpreB1λ5Cκ and Hs_VpreB1λ5Cκ decreased the affinity for 
4-hydroxy-3-nitrophenylacetic acid (NPA) when paired with IGHV1-72Cγ (Fig. 7A); 
the replacement of Arg with Tyr also appeared to affect the heat stability of paired 
complexes (Fig. 7B).  
 
Effects on the substitution of human-derived Cκ for Cλ5  
The originally designed VpreB1λ5 light chains were connected to a human-derived 
Igκ constant region (Fig. 3). I also tested binding capacity after the replacement of the 
human-derived Igκ constant region with the human-derived Igλ5 constant region by 
ELISA test (Fig. 8). The concentration of the antibody in cell culture supernatant was 
adjusted to the same. Standard curves were constructed using a purified 
influenza-specific human IgG recombinant antibody at serial dilutions. When the 
concentration of the reference was between 25 and 400 ng/mL (50 and 800 ng/mL), a 
linear relationship was obtained between absorbance and concentration in the fitted 
curve, with R2 > 0.97 (Fig. 9A); the acceptable recoveries were shown in different 
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concentrations (Fig. 9B). The antibody capacities were significantly reduced by the 
replacement with λ5 constant region (Fig. 10), which were consistent with the results of 
NPA-binding in silico (Fig. 11). Thus, human-derived Igκ constant region was used in 
all of my “common light chain” models.  
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Discussion 
 I modified the SLC structures to attempt to design the “common light chains” 
(VpreBλ5Cκ), which might be able to pair with broad-spectrum antigen-specific heavy 
chains detected by the formerly reported method.  
 Previously, the mice were immunized with NP-CGG and CGG antigens, and the NP- 
and CGG- specific IgH gene repertoires were exhaustively analyzed using NGS (Kono 
et al., 2017), to address the lack of information regarding paired light chains, I focused 
on the maturation process of B-cell receptors in the early stage of B cell development. 
Theoretically, the SLC would most likely exist as a “common light chain” to different 
heavy chains. The structures of the SLC show remarkable homology with the 
conventional light chain (Ohnishi and Melchers, 2003), the SLC could be transformed 
into a structure similar to the conventional light chain. 
The similar work focusing on variable domain of the modified SLC has been 
successfully performed (Morstadt et al., 2008). Further, for the study on pairing of IgH 
and IgL, the recombinant light chains from different species and isotypes were 
synthesized, which were linked to a human Igκ constant region for expressing an intact 
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light chain. I aimed to design a light chain with extensive matching to the heavy chains 
and maintain the antigen specificity and affinity after matching.  
By classification analysis using protein sequences, it was found that the VpreB1 and 
VpreB2 sequences were similar, however VpreB3 sequences were quite different. 
Initially, to analyze the antigen binding, I constructed all three VpreB1λ5 light chains 
(Mm_VpreB1λ5, Hs_VpreB1λ5 and Hs_VpreB3λ5) in silico. In fact, because the 
former constructed two human-derived VpreB1λ5 seemed fail to maintain the binding 
capacity of IGHV1-72, especially the Hs_VpreB3λ5 lost more binding affinity of both 
IGHV1-72 and IGHV9-3. After this, I constructed the mouse-derived VpreB1λ5 light 
chain. 
  Because the positively charged Arg(+) was frequently found in CDR3 of 
poly-reactive (auto-reactive) antibodies and it does not exist in the original λ1 light 
chain. Here, to analyze the possible effects of the positively charged Arg on antigen 
binding, Arg was replaced by the uncharged Tyr. The effect of the mutation of Arg to 
Tyr (RtY) in CDR-L3 on antigen binding was discussed by in silico simulation. After 
docking for NP binding, I found that the Args in the middle of CDR-L3 in both 
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Mm_VpreB1λ5Cκ and Hs_VpreB1λ5Cκ decreased the affinity for NP when paired 
with IGHV1-72Cγ. The residue scan showed that the RtY mutation also appeared to 
improve the thermal stability of paired complexes. So the RtY mutation was introduced 
into the “common light chain” models. 
 The variable domain of the antibody is significant in antigen recognition. In recent 
years, the effects of light chain constant regions on antibody expression and antigen 
binding have been studied (Lee et al., 1999; Janda et al., 2016). The effect of JC regions 
of λ5 or κ on heavy chain maturation and cell surface expression in pre-B cell lines was 
researched, the result showed that the mouse-derived λ5 JC region and κ JC region were 
used to co-express with several types of HC and JC λ5 promotes heavy chain 
maturation and expression more significantly compared to JC κ (Smith and Roman, 
2010). However, the effect on the antigen affinity of heavy chain was not yet known. In 
this study, I compared the effects of the Igκ constant region and Igλ5 constant region on 
antigen binding for NP and CGG. Significant differences were noted in some cases in 
antigen binding. I continued to use the original Igκ given by the expression vector in my 
models. 
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  Further, all the constructed antibodies consisting of the SLC-modified light chain and 
the mouse-derived antigen specific heavy chain were examined for antigen binding 
capacities to confirm the conception of “common light chain”.   
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Chapter 2 
 
Pairing of constructed light chain models to IgHs and their effect on 
antigen recognition of IgHs 
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Introduction 
During B cell development, the rearrangement of IgH genes occurs before that of 
IgL genes, where the surrogate light chain (SLC) is associated with nascent IgH in place 
of IgL, and as reported before, approximately 50% of the newly rearranged heavy 
chains can bind to surrogate light chain at the pre-B stage and differentiate into mature 
B cells (Boekel et al., 1997). The variable domains of antibody heavy chains show rich 
diversity and are encoded by three different loci, that is, the variable (V), diversity (D), 
and joining (J) gene segments (Tonegawa, 1983). Nucleotide addition in the 
complementarity-determining region (CDR) 3 hypervariable region provides additional 
diversity for antigen recognition and binding (Xu et al., 2000). The light chain variable 
region (VL) is less diverse than those of the heavy chain variable region (VH) because of 
the lack of D gene segments (Jackson et al., 2013). Besides, by the comparison of SLC 
and conventional light chain sequences, it was found that the similar CDR regions of 
conventional light chain also existed in SLC (Ohnishi and Melchers, 2003). Thus, the 
surrogate light chain might have a propensity to be modified to the conventional light 
chain and be associated with a wide range of IgHs. 
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In the previous study, NGS method was used to analyze the antigen-specific 
antibody responses. The specific IgH repertoires were determined by the common 
antibody repertoire in immunized 5 mice. In the Naïve mice group, there was no 
antigen-responding antibody repertoire detected. In NP-CGG and CGG immunized 
mice groups, it was found that the major responding IgHs were IGHV1-72 for 
NP-hapten and IGHV9-3 for CGG-carrier protein. IGHV1-72 is the well-known 
NP-responding antibody and the detected CGG-responding IGHV9-3 is the new finding. 
The antigen specificities were confirmed by gene synthesis of NGS reads. In silico 
analysis of antigen-specific antibody was done to confirm their antigen specificities 
initially, then the antibody protein expression experiments were performed.  
  In the constructed antibodies, all of the constant regions are given by the expression 
vectors. The λ1 variable domain is known as the original pair of IGHV1-72. Because 
the IgH/IgL pairing could not be predicted by the protocol, so the λ1 variable domain 
was also used to pair with IGHV9-3 for confirming the CGG specificity. After stable 
expression, the cell culture supernatants were collected and examined for antigen 
specificity. As the result shown, when only CGG was as the antigen, IGHV1-72 
 34 
antibody did not react as expected, and IGHV9-3 antibody reacted with CGG in a low 
but significant reactivity. It was confirmed that IGHV9-3 is actually the CGG specific 
heavy chain. However, compared to the reactivity of IGHV1-72 to NP, the reactivity of 
IGHV9-3 to CGG was very low. Here, I thought that the pairing of IgH and lgL was 
improper and had impact on the antigen binding. The following work, I focus on the 
analysis of IgH/IgL pairing. 
In this study, I constructed the engineered “common light chain” (VpreBλ5Cκ) 
models from two species. In order to examine the matching to IgHs, firstly, the 
constructed light chains were paired with two representative IgHs (NP-specific 
IGHV1-72 and CGG-specific IGHV9-3). In addition, the conventional IgLs were also 
constructed as controls. The expression and secretion of paired IgH/IgL complex was 
confirmed by Western Blot of the culture supernatant. My results suggested that the 
Mm_VpreB1λ5Cκ seemed to have the potential to be the “common light chian”. 
Besides, the CDR3 region of IgH is usually considered as the most important 
antigen-binding site. However, in the detected antigen-specific IgH repertoires reported 
before, it was known that a critical binding site (R50) is located in CDR2 in NP-specific 
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IGHV1-72 (Mizutani et al., 1995) and considerable CGG-specific IGHV9-3 repertoires 
containing the same variable region and different diversity and joining regions (Kono et 
al., 2017). Here, I also examined the possible antigen-binding site in both these two 
IgHs and analyzed the binding patterns by in silico simulation and antibody expression 
experiments. My finding showed that the different effects on the paired IgLs between 
small antigen binding (NP hapten) and protein antigen binding (CGG carrier). 
The purposes of my study were as follows. 1. Understanding of the dynamics of 
IgH/IgL pairing. 2. Analysis of the effect of IgL pairing on antigen binding of IgH. As 
far as I know, there is no research on these questions. 3. Construction of the artificial 
light chain that pairs with a broad range of heavy chains. It means to search for the 
“common light chain”. 
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Materials and Methods 
Cell culture 
This was performed as described in Chapter 1. 
 
DNA plasmids and antibody gene synthesis 
This was performed as described in Chapter 1.   
 
Transfection and antibody protein expression 
This was performed as described in Chapter 1. 
 
Immunoassays 
This was performed as described in Chapter 1.  
To determine the binding affinity of the antibodies (Fig. 19), the serial diluted 
concentration of antibody samples and the constant concentration of antigens (5 µg/mL) 
were used. The steps for the ELISA were the same as those described above. 
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Western blot analysis 
  Antibody expression in the supernatant was analyzed by western blotting. The 
antibodies from the supernatant were separated using 12% SDS-PAGE and 
electroblotted onto 0.45-µm nitrocellulose membranes (Bio-Rad). Then, 5% skim milk 
in wash buffer (50 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 0.05% v/v Tween-20) was used 
for blocking at 4°C overnight. The immunoblot was treated with HRP-conjugated goat 
anti-human IgG (H+L) antibody (Jackson ImmunoResearch) (Fig. 12) or 
HRP-conjugated goat anti-human IgG (Dako) and HRP-conjugated goat anti-human Igκ 
(SouternBiotech) (Fig. 21) at 1:5000 dilution. SuperSignal West Femto (Pierce) was 
used as the substrate for chemiluminescence. 
 
In silico simulation 
This was performed as described in Chapter 1. 
After docking, all the complexes were refined by a short MD simulation for 5 ns in 
NAMD (https://www.ks.uiuc.edu/Research/namd/) with the Amber12: EHT force field 
and R-field solvation. The protocol was as follows: all the complexes were put into a 
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water box with periodic boundary conditions and the margin was set to 10Å; energy 
minimization for the whole system was performed by applying gradient minimization 
until the RMS gradient fell below 0.05 kcal mol-1 Å-1; heating for 10 ps from 0 K to 310 
K; equilibration for 10 ps at 310 K; production phases for 5 ns at 310 K. The stable 
conformations were analyzed for NPA-binding.   
   
Statistical analysis 
  This was performed as described in Chapter 1. 
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Results 
Pairing of constructed light chain models to IGHV1-72 and IGHV9-3 
The synthesized genes in the pTAKN vector were inserted into an 
antibody-expression vector (Mammalian Power Express System, Toyobo) containing 
the human-derived Igγ1 heavy chain constant region gene and the Igκ light chain 
constant region gene. The expression and secretion of paired IgH/IgL complexes were 
confirmed by western blot of culture supernatants, showing that all light chain models 
(Mm_VpreB1λ5Cκ, Hs_VpreB1λ5Cκ, and Hs_VpreB3λ5Cκ) were paired with 
IGHV1-72Cγ and IGHV9-3Cγ heavy chains (Fig. 12).   
 
Interaction patterns between receptor and ligand in IGHV1-72 antibodies 
To assess the stereo-chemical qualities and antigen bindings of NP-specific IgHs 
paired with each light chain model (Mm_λ1Cκ, Mm_VpreB1λ5Cκ, and 
Hs_VpreB1λ5Cκ). The crystal structure 1NGP was as the control, which is the original 
structure of IGHV1-72/Mm_λ1 antibody. In silico docking simulations were performed, 
after 5ns molecular dynamic simulation, the optimized conformations were evaluated 
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using Procheck (Fig. 13). The optimal antigen binding patterns were analyzed. The 
structures of 1NGP and IGHV1-72Cγ/Mm_λ1Cκ have the same antibody variable 
domains and antigen. The interaction of the IGHV1-72Cγ/Mm_λ1Cκ complex was 
similar with the crystal structure (1NGP). The NP-specific IGHV1-72Cγ paired with 
Mm_λ1Cκ, Mm_VpreB1λ5Cκ, and Hs_VpreB1λ5Cκ showed the conserved 
antigen-binding site Arg50 in all three antibodies; however, Arg50 was found to bind to 
different oxygen molecules in IGHV1-72Cγ/Mm_λ1Cκ (Fig. 14). 
 
Prediction of the antigen-binding sites in IGHV9-3 
The dominant CGG-specific IgH repertoires include the same VH (IGHV9-3) and 
different DH and JH regions (Fig. 15), suggesting that the antigen specificity was not 
exerted by CDR-H3. To test the involvement of CDR-H1 and CDR-H2 in antigen 
binding, several mutations were introduced into CDR-H1 and -H2 (Fig. 16A). As 
shown in Fig. 14, Arg50 of IGHV1-72 was predicted to be one of the major residues to 
interact with NP. Consistently, the R50A mutant remarkably lost its antigen binding 
affinity (Fig. 16B). Similarly, all mutations in CDR-H1 and CDR-H2 of IGHV9-3 
 41 
significantly induced a loss of binding affinities, suggesting that these regions were 
involved in the binding to CGG (Fig. 16B).  
 
Comparison of binding capacities among the “common light chain” candidates in 
silico  
  In order to predict the antigen binding capacities of NP-specific IgHs paired with 
each light chain models (Mm_VpreB1λ5Cκ, Hs_VpreB1λ5Cκ), the docking 
simulations were performed. The binding energies as the docking result were compared. 
I used both general models and induced-fit models to do the docking simulation with 
NPA. The results of general models are in accordance with those of induced-fit models. 
In addition, comparing the docking results and the ELISA test, it showed that the 
predicted results and the detected results are generally consistent (Fig. 7 and Fig. 17). 
The Mm_VpreB1λ5Cκshowed higher binding energy than Hs_VpreB1λ5Cκ, though 
compared to the original light chain (Mm_λ1), the binding energy is lower (Fig. 7).    
 
Mm_VpreB1λ5Cκ  maintained the binding capacities of IGHV1-72 and IGHV9-3 
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Among the light chain models constructed, Mm_VpreB1λ5Cκ properly maintained 
the binding of IGHV1-72 to NP antigen, although its binding capacity with the original 
light chain (Mm_λ1Cκ) was significantly higher. In addition, Mm_VpreB1λ5Cκ also 
maintained a high binding capacity of IGHV9-3 to CGG, whereas pairing with 
Mm_λ1Cκ decreased the binding capacity remarkably (Fig. 17). Hs_VpreB1λ5Cκ 
showed significant non-specific binding to NP-BSA, when paired with IGHV9-3 (Fig. 
17). I also compared the non-specific binding to NP-BSA between Mm_VpreB1λ5Cκ 
and Hs_VpreB1λ5Cκ in silico, when paired with IGHV9-3 (Fig. 18). The result showed 
a higher binding energy, when IGHV9-3 paired with Hs_VpreB1λ5Cκ, which is 
consistent with the ELISA test.  
 
Mm_VpreB1λ5Cκ  maintained the binding affinities of IGHV1-72 and IGHV9-3 
I also detected the antigen binding by serial dilution of antibody concentration. In the 
NP-BSA binding test, the NP antigen was recognized at the concentration of 0.8 µg/mL 
when IGHV1-72 paired with Mm_VpreB1λ5Cκ and Mm_λ1Cκ, however it was 
recognized by other antibodies at higher concentrations; In the CGG-binding test, the 
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CGG antigen was recognized at the concentration of 0.2 µg/mL when IGHV9-3 paired 
with Mm_VpreB1λ5Cκ, while it was recognized at higher concentration when 
IGHV9-3 paired with Mm_λ1Cκ (Fig. 19). These results suggested that 
Mm_VpreB1λ5Cκ had the ability to pair with either IGHV1-72 or IGHV9-3 
maintaining the antigen recognitions of IgHs. 
 
Differences between the binding pattern of small molecule antigen (NP hapten) 
and protein antigen (CGG carrier) 
  It is noteworthy that conventional IgLs, Vκ_2ORB and Vκ_2A6I, considerably 
maintained the antigen binding of IGHV9-3 but not that of IGHV1-72 (Fig. 17 and Fig. 
19), suggesting that the significant differences on the conventional IgLs pairing with 
different IgHs. Combined the results above together. It suggested that the protein 
antigen (CGG) binding to IGHV9-3 antibodies is less affected by the IgL; the NP 
hapten as small molecule binding to the IGHV1-72 antibodies is significantly affected 
by IgLs. These results showed the differences between the binding pattern of small 
molecule antigen and protein antigen.  
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Discussion 
I modified the SLC structures to construct three “common light chain” candidates. It 
was found that the chimeric genetic engineering antibody consisting of a mouse-derived 
variable region and a human-derived Igκ constant region could pair with both of heavy 
chains (IGHV1-72 and IGHV9-3) without losing the heavy chain antigen specificity and 
could maintain the affinity derived from heavy chains to a certain extent.  
  I did the in silico analysis of the binding pattern of constructed antibodies to NP 
antigen. In order to analyze the interaction between antibody and antigen, the crystal 
structure 1NGP was as the control, which is the original structure of IGHV1-72/Mm_λ1 
antibodies and the other three models were also constructed. in silico docking 
simulations were performed and the optimal antigen binding poses were analyzed. In 
these three constructed structures, the conserved antigen-binding site Arg50 was shown; 
however Arg50s were found bound to different oxygen molecules in 
IGHV1-72Cγ/Mm_λ1Cκ, suggesting that the change of paired light chains might result 
in the broken of the original hydrogen bond. It implies that the binding pattern of 
IGHV1-72 to NP is affected by paired IgLs. 
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All the light chains tested matched with IGHV9-3 and maintained the reactivity to 
CGG. V9-3 combined several different diversity (D) and joining (J) regions to form 
different IGHV9-3 antibodies. In the variable domain, CDR1 and CDR2 are only 
encoded by the V region, whereas CDR3 includes a portion of the V regions and all of 
the D and part of the J regions (Xu and Davis, 2000). Taken together, these findings 
suggest that the main domain of antigen recognition in IGHV9-3 might be more likely 
to be located on CDR1 and CDR2. I also confirmed the effect of several amino acids in 
CDR1 and CDR3 of IGHV9-3 on binding affinity. Although the effect of different light 
chains on CDR-H1 and CDR-H2 is not known, this is probably the reason why 
IGHV9-3 maintained its reactivity to CGG after matching with different light chains. 
All the antibodies of the human-derived light chain that bound to the mouse-derived 
heavy chain had low affinities for NP-BSA. This might be related to the differences 
between species. Depending on the distance between residues on the VH-VL interface, 
the antibodies were divided into three different clusters. Two representative light chains 
were chosen as the control to pair with both IGHV1-72 and IGHV9-3: the 
human-derived cluster A light chain (PDB: 2ORB.L) and mouse-derived cluster B light 
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chain (PBD: 2A6I.L). Mouse antibodies include a part of Cluster A and Cluster B, 
whereas human antibodies all belong to Cluster A (Chailyan et al., 2011). It implies that 
the mouse-derived light chains might have wider compatibility than the human-derived 
light chains. 
  According to these results, it showed the significant differences between two 
conventional IgLs when paired with different IgHs. The two conventional IgLs 
(2ORB.L and 2A6I.L) preserved the antigen binding affinity of IGHV9-3, suggesting 
that the surface to surface wide interaction between antigen and antibody (CGG and 
IGHV9-3 antibody) is less affected by the conformation skew brought by the IgLs. 
However, the two conventional IgLs failed to preserve the antigen binding affinity of 
IGHV1-72. NP hapten as small molecule binds to IGHV1-72 antibodies, the mode of 
antigen binding (IGHV1-72 antibody to NP) would be “lock and key” mode, thus prone 
to the conformation skewing by IgLs. It might elucidate that why the Mm_VpreB1λ5Cκ 
maintained the binding capacity of IGHV1-72 but Hs_VpreB1λ5Cκ did not, while both 
two VpreB1λ5Cκ maintained the binding capacity of IGHV9-3 to CGG. 
The current findings, together with our previous study involving the use of NGS for 
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exhaustive analysis of antibody repertoires, provide a new approach for recognizing 
antigen-specific antibodies and the pairing of heavy and light chains and also aid in the 
artificial expression of important antigen-specific heavy chains for which data on paired 
light chains are not available.  
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Chapter 3 
 
Mm_VpreB1λ5Cκ can pair with several IgHs 
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Introduction 
  To confirm the antigen specificity of the IgH repertoires detected, I attempted to 
express the related antibodies in vitro by using gene synthesis technology. However, 
after immunization, a wide variety of light chain repertoires were produced and the 
corresponding light chain that would be well matched with the heavy chain repertoires 
detected could not be predicted by our method. My aim was to find a “common light 
chain” to pair with a broad range of heavy chains. 
  Based on the property of SLC, I designed several versions of genetically engineered 
“common light chain” prototypes by modifying the SLC structure. Among them the 
Mm_VpreB1λ5Cκ light chain showed acceptable matching property with two different 
heavy chains (IGHV1-72 and IGHV9-3) without losing specificity from the original 
heavy chains.  
Further, I detected the matching of Mm_VpreB1λ5Cκ and more antigen-specific 
IgHs. Another three IgHs were chosen as NP-specific and CGG-specific IgH repertoires, 
respectively. Using artificial antibody expression, I examined the matching and 
antigen-binding capacity of the light chain designed to the different heavy chain 
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samples. The mouse-derived VpreBλ5 light chain showed a good match with several 
different heavy chains without losing specificity to the original heavy chains. Thus, the 
results suggest that engineered light chains could effectively help solve the issues 
related to the expression of the antigen-specific heavy chains detected by NGS and are 
of significance in vaccine development. 
In this study, I used the mouse-derived IgHs as the heavy chain models to examine 
the matching of both mouse- and human-derived VpreBλ5 IgLs. Although the mouse- 
and human-derived IgHs keep the genetic similarities to some extent, the current results 
showed that the human-derived IgL could not well pair with mouse-derived IgHs. I 
thought that the “common light chain” probably should be considered in different 
species. To test my hypothesis, I used the Mm_VpreB1λ5Cκ and Hs_VpreB1λ5Cκ to 
pair with three reported IgHs from different families of human and mouse. The 
constructed antigen-antibody complexes from mouse and human were performed with 5 
and 10 ns molecular dynamic simulation using Amber14, respectively. The binding 
energies were calculated after the conformation kept stable with MMPBSA method. 
The results showed that all the VpreBλ5 light chain antibodies maintained certain 
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binding capacity to corresponding antigens, compared to the original antibody 
structures. 
In conclusion, based on the property of SLC, the genetically engineered VpreBλ5 
light chains by modifying the SLC structure might have the potential to be the 
“common light chain”. 
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Materials and Methods 
Cell culture 
This was performed as described in Chapter 1. 
 
DNA plasmids and antibody gene synthesis 
This was performed as described in Chapter 1.   
 
Transfection and antibody protein expression 
This was performed as described in Chapter 1. 
 
Immunoassays 
This was performed as described in Chapter 1.  
In Fig. 22, cell culture supernatants were incubated with antigens (5 µg/mL) 
pre-coated in microtiter plate wells. The other steps were the same as those described 
above. The binding activities of the antibodies are expressed in terms of O.D. 490 nm. 
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Western blot analysis 
  This was performed as described in Chapter 1. 
 
Gene classification 
  This was performed as described in Chapter 1. 
   
Statistical analysis 
This was performed as described in Chapter 1. 
 
In silico simulation 
This was performed as described in Chapter 1. 
The final models were docked with peptides from the crystal structures (shown in Fig. 
23) in Protein Data Bank using Protein-Protein Docking in MOE. 
After docking, the molecular dynamics simulations were performed in Amber with 
the ff14SB force field. The protocol was as follows: all the complexes were put into a 
10Å water box with periodic boundary conditions; initially, energy minimization for 
water and ions was performed with 1000 steps of conjugate gradient methods; energy 
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minimization for all atoms was performed using 200 steps of steepest descent method, 
followed by 4800 steps of conjugate gradient method; heating for 10 ps from 0 K to 310 
K; equilibration for 10 ps at 310 K under 1 atmosphere conditions; production phases at 
310 K. The stable conformations were analyzed for binding energy using MM/PBSA 
method in Amber16 software (Srinivasan, Cheatham et al. 1998; Kollman, Massoya et 
al. 2000). 
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Results 
Mm_VpreB1λ5Cκ  can pair with several IgHs 
To examine the ability of Mm_VpreB1λ5Cκ to match with different heavy chains, 
three additional NP-specific IgHs (IGHV1-53/D1-1/J2, IGHV6-3/D1-1/J2, and 
IGHV14-3/D1-1/J2) and three CGG-specific IgHs (IGHV1-69/D1-1/J2, 
IGHV1-55/D1-1/J3, and IGHV1-52/D2-4/J2) were chosen and then we tested the 
preservation of antigen binding of each IgH (Fig. 20). These chosen antigen-specific 
IgH repertoires were classified. Phylogenetic tree was generated using the 
neighbor-joining (NJ) algorithm (Fig. 20). It suggested that all these IgHs belong to 
several families. 
Western blot analysis of the cell culture supernatants confirmed the expression and 
secretion of all antibodies. The molecular weight (~55 kDa) of the heavy chains and the 
different molecular weights (~25 kDa) of the light chain (Mm_VpreB1λ5Cκ) were 
observed (Fig. 21), suggesting that all the chosen IgHs paired with Mm_VpreB1λ5Cκ 
and all the antibodies were secreted out of the cell successfully. 
All the examined antibodies significantly bound to the corresponding original 
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antigens maintaining the specificity and affinity and showed significantly greater 
binding capacity than the negative control (CHO medium), suggesting that 
Mm_VpreB1λ5Cκ is able to pair with a wide variety of IgHs maintaining their antigen 
specificities (Fig. 22). 
 
In silico simulation of Mm_VpreB1λ5Cκ  and Hs_VpreB1λ5Cκ  pairing with IgHs 
from different clans 
IgHs derived from different clans, were chosen as samples for testing the binding 
capacity, including the mouse-derived IgH sequences from the reported structures (PDB 
ID): 1A3R, 5EOQ and 2HRP (Fig. 23A) (Torom et al., 1994; Kaever et al., 2016; 
Lescar et al., 1997); the human-derived IgH sequences from the reported structures 
(PDB ID): 5ERW, 3MOD and 4XMK (Fig. 23B) (Kachko et al., 2015; Yang et al., 
2013; Kumar et al., 2015).  
Induced-fit homology modeling was used to construct the VpreB1λ5Cκ antibody. 
The binding energies were calculated preliminarily from the docking result. The small 
RMSD values between the co-crystallized and the docked ligands were shown and it 
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proved that the docking structure were good (Fig. 24). The Plots for the calculated 
binding energies between the original structures and VpreB1λ5Cκ antibody structures 
were shown as docking score (Fig. 25), the similar binding energy suggested that the 
VpreB1λ5Cκ light chain can pair with the corresponding IgHs and maintain the binding 
affinity of IgHs. 
5ns molecular dynamics simulation was performed for mouse-derived antibody 
complex and 10ns molecular dynamics simulation was performed for human-derived 
antibody complex (Fig. 26 and Fig. 27). The trajectories from the stable conformations 
were chosen for the calculation of binding energy with MM/PBSA method. The binding 
energies between the original and VpreB1λ5Cκ structures were compared (Fig. 28), and 
the results suggested that Mm_VpreB1λ5Cκ and Hs_VpreB1λ5Cκ might pair with IgHs 
from different clans maintaining their specificities.   
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Discussion 
 
I designed an engineered light chain, which can associate with several different 
heavy chains from mouse antibodies. The IgHs from several families detected before 
were utilized to pair with mouse-derived VpreB1λ5 to determine the matching of IgH 
and IgL. These data imply that the Mm_VpreB1λ5 light chain showed a good match 
with several different heavy chains without losing specificity of the original heavy 
chains. However, the study has some limitations, such as limited samples and low 
affinities. On the one hand, the low affinity might be caused by the original binding 
capacity from IgHs. On the other hand, it might because the affect of paired IgL. In 
further studies, I plan to work on the matching of heavy chains from different species 
and to further improve binding affinity after matching through genetic modification on 
VpreBλ5 light chains.  
  In addition, I considered the “common light chain” in different species and analyzed 
the mouse- and human-derived VpreB1λ5Cκ light chain pairing with the reported IgHs 
from corresponding species. In silico simulation showed that, comparing with the 
original structures, mouse- and human-derived VpreB1λ5Cκ were well-matched with 
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heavy chains from different clans and maintained the antigen binding capacity of the 
original antibodies to some extent. Although the experimental data is still in simulation 
stage. 
In summary, Mm_VpreB1λ5Cκ, has the potential to be a “common light chain”, 
providing a novel system to dissect the mode of IgH/IgL interaction and contributing a 
new seed for antibody drug development. Mm_VpreB1λ5Cκ could be used as a 
standard light chain, which can associate with wide varieties of IgHs, and it would be 
possible to examine the properties of IgHs without the bias of inherent light chains. It 
could be as a novel tool to investigate the IgH/IgL interaction dynamics.  
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General Discussion 
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  In this study, I ascertained that the chimeric antibody consisting of a mouse-derived 
SLC variable region and a human-derived Igκ constant region could pair with several 
IgHs without losing the IgH antigen specificity and could maintain the antigen affinity 
of IgHs to a certain extent.  
  Previously NP- and CGG- specific IgH repertoires and their dynamics on a whole 
were analyzed using NGS, and utilized the gene synthesis and expression system for the 
evaluation of important antibodies; however, the antigen binding seemed significantly 
affected by the chosen IgL (Kono et al., 2017). I thought that if the antigen binding of 
both IgH and IgL can be separately analyzed, it would provide a novel experimental 
system to dissect the antigen binding dynamics of an antibody. I hypothesized that if the 
standard IgL, which can associate with a wide variety of IgH can be used, it would be 
possible to examine the molecular properties of IgHs without the bias of various 
inherent light chains. For the model of IgH/IgL pairing, it was reported that some IgLs 
can be shared by more than one IgH because IgL is less diverse than IgH (Jackson et al., 
2012; Hoi and Ippolito, 2013).  
  The SLC would most likely exist as a “common light chain” for different IgHs 
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because peripheral B cells use SLC for their IgH counterparts during their early 
development in the bone marrow (Karasuyama et al., 1990; Mårtensson et al., 2010; 
Melchers, 2015). Because the structures of the SLC remarkably show homology with 
the conventional IgL (Ohnishi and Melchers, 2003), I tried to transform the SLC 
molecules to construct “common light chain” models. A similar work focusing on the 
variable domain of SLC has been reported, but the ability to pair with IgHs was not 
evaluated (Morstadt et al., 2008).  
  The Mm_VpreB1λ5Cκ molecule is associated with NP-specific IGHV1-72 IgH and 
CGG-specific IGHV9-3 IgH maintaining the antigen specificities and abilities, whereas 
Hs_VpreB1λ5Cκ and Hs_VpreB3λ5Cκ showed incomplete maintenance of antigen 
specificities. I tested the replacement of Cκ with Cλ5 but the antigen binding properties 
were not improved. 
  It was reported that, depending on the distances and interactions between residues on 
the VH-VL interface, antibodies can be classified into three different clusters (Mouse 
antibodies are grouped into both Cluster A and Cluster B, whereas human antibodies all 
belong to Cluster A) (Chailyan et al., 2011). This implies that some mouse-derived IgLs 
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might have wider heavy chain compatibility than human-derived IgLs. Two 
representative lgLs were chosen as the control to pair with both IGHV1-72 and 
IGHV9-3: the human-derived cluster A IgL (PDB: 2ORB.L) and mouse-derived cluster 
B IgL (PBD: 2A6I.L). Surprisingly, the conventional IgLs, mouse 2A6I.L and human 
2ORB.L, preserved the antigen binding affinity of IGHV9-3; however, these 
conventional IgLs failed to preserve the antigen affinity of IGHV1-72, suggesting 
significant differences in these IgH properties. IGHV9-3 used various IGHD genes in 
binding to CGG antigen, suggesting that the major antigen binding sites is CDR-H1 or 
CDR-H2. In fact, mutations in CDR-H1 and CDR-H2 impaired CGG binding. I 
speculate that the wide surface-to-surface interaction of an antigen and an antibody is 
less affected by the conformation skew induced by IgL species. In contrast, IGHV1-72 
mainly used IGHD1-1 for NP-binding, suggesting that the major binding site is 
CDR-H3 in addition to R50 in CDR-H2. In this case, the mode of antigen binding 
would be “lock and key” mode, which is prone to conformational skewing by the 
chosen IgL. In this context, Mm_VpreB1λ5Cκ was able to preserve the antigen 
recognitions of these distinct IgHs. 
 64 
In this study, I constructed an engineered “common light chain” prototype, 
Mm_VpreB1λ5Cκ, which can associate with several IgHs. It would be possible to 
improve the versatility of Mm_VpreB1λ5Cκ by in silico simulations and immunoassays 
to provide a novel antibody model in which the interference between IgH and IgL is 
properly controlled and insulated for optimized antigen recognition of artificial 
antibodies. 
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Figures 
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Fig. 1: Concept of the “common light chain”. During B cell development, 
approximately 50% of the newly rearranged heavy chains can bind to the surrogate light 
chain at the pre-B stage and differentiate into mature B cells. Thus, the surrogate light 
chain might have a propensity to be the common light chain associating with most of 
the heavy chains in the periphery. 
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Fig. 2: Comparison between human-derived conventional light chain sequence 
(PDB: 3PIQ, bottom) and surrogate light chain sequence (PDB: 2H32, top) after 
alignment. The identical amino acids are indicated at the top of the sequence. Non-Ig 
region, J region, and CDR3 are annotated in green, orange, and purple, respectively. 
The red arrow indicates the positively charged Arg in the middle of VpreB (PDB: 
2H32).   
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Fig. 3: Construction of recombinant VpreBλ5Cκ  light chains. Structural map of the 
genetically engineered light chain. VpreB (red), Cκ (purple), and heavy chain (orange) 
are shown. The “tail” of λ5 is highlighted in blue, and the non-Ig domain of VpreB is 
highlighted in green. The mutation from Arg to Tyr in CDR-L3 was annotated. The 
steps involved in genetic modification (left) are labeled in appropriate order: 1. Cut the 
“tail” of λ5; 2. Cut and remove the non-Ig region of VpreB; 3. Splice the “tail” of λ5 to 
VpreB; 4. Introduce the mutation of Arg101Tyr into VpreB; 5. Replace the λ5 with the 
human-derived Cκ. The intact antibody Fab (right) is also shown. In addition, all the 
variable regions of IgHs were connected with the human derived Igγ constant region as 
described in Materials and Methods. 
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Fig. 4: Alignment of the partial amino acid sequences of VpreB1 and λ5 compared 
to that of those of VpreB1λ5 constructs derived from humans and mice. The 
variable regions of VpreB1λ5 and the corresponding regions in VpreB1 and λ5 are 
indicated in red, blue, and orange, respectively. The non-Ig region in VpreB is indicated 
in green. The mutation of Arg to Tyr is also highlighted in purple. The CDR regions in 
VpreB1λ5 constructs are annotated using the Kabat numbering scheme. 
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Fig. 5: Construction of Hs_VpreB3λ5. (A) Phylogenetic tree for different VpreB 
genes from several species. The tree was generated using the neighbor-joining (NJ) 
algorithm with the MEGA7 software. (B) Comparison between Hs_VpreB1λ5 and 
Hs_VpreB3λ5 sequences. The CDRs are annotated in purple. 
 
B
A
! " "A"$$$$$$6$$6$$$$$$$$$$$$2$92$$$$$0$$$$$667$$$$7$22$$8$$$$$$$$$$7-8
$$$$$$$$$$$$$$$6263882990729927
086677-227-86818667-8$

$$$$$$$$$$$$$$$626222-662892869078667872278707-8$$
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$7$$$$$$$$$$$$$$$$$$$$$$$$$7

! " "A"$$$$$$$$1$$$$$2$08$$6$$$$$$$89-896292$$$$
$$$$$$$$$$$$$$$817728082633
89-896292$
$$$$$$$$$$$$$$$1290868889-896292$	

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$7
		*
*

 VpreB1 Mouse
 VpreB2 Mouse
 VpreB1 Rat
 VpreB2 Rat
 VpreB1 Dog
 VpreB1 Chimp
 VpreB1 Human
 VpreB3 Dog
 VpreB3 Chimp
 VpreB3 Human
 VpreB3 Mouse
 VpreB3 Rat
0.10
Hs_VpreB1λ5      
Hs_VpreB3λ5 
       
 
 
 
                         
Hs_VpreB1λ5     
Hs_VpreB3λ5 
$$$$$$$$$$$$$
 84 
Fig. 6: Homology modeling for the “common light chain” antibodies. (A) The 
similarity between the template (the sequences from 1NGP) and the constructed 
antibodies are shown: IGHV1-72Cγ/Mm_λ1Cκ (left), IGHV1-72Cγ/Mm_VpreBλ5Cκ 
(middle), IGHV1-72Cγ/Hs_VpreBλ5Cκ (right). (B) Ramachandran plot for evaluating 
the constructed antibody structures. IGHV1-72Cγ/Mm_λ1Cκ (left), 
IGHV1-72Cγ/Mm_VpreBλ5Cκ (middle), IGHV1-72Cγ/Hs_VpreBλ5Cκ (right). 
  
-D
oc
ki
ng
 S
co
re
 (K
ca
l/m
ol
)
-D
oc
ki
ng
 S
co
re
 (K
ca
l/m
ol
)
A
B
    IGHV1-72/Mm_λ1Cκ IGHV1-72/Mm_VpreB1λ5Cκ                             IGHV1-72/Hs_VpreB1λ5Cκ 
          IGHV1-72/Mm_λ1Cκ IGHV1-72/Mm_VpreB1λ5Cκ                       IGHV1-72/Hs_VpreB1λ5Cκ 
 85 
 
 
Fig. 7: The effects of the mutations from Arg to Try in CDR3 of VpreBλ5Cκ light 
chains. (A) Docking for NPA binding. IGHV1-72/Mm_λ1 serves as the reference. 
Docking score (free energy of binding) are shown. (B) Residue scan performed for 
R101 in the antibody-antigen complex: IGHV1-72Cγ/Mm_VpreBλ5Cκ (left) and 
IGHV1-72Cγ/Hs_VpreBλ5Cκ (right). The mutation R101Y causing the increase in 
stability is highlighted in red. 
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Fig. 8: Comparison between human kappa constant region and human lambda5 
constant region. The replacement of the human-derived Igκ constant region with the 
human-derived Igλ5 constant region was performed. 
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Fig. 9: A representative curve fitting for concentration measurement. (A) When the 
concentration of the reference was between 50 and 800 ng/mL, a linear relationship was 
obtained between absorbance and concentration in the fitted curve, with R2 > 0.97. (B) 
The recoveries were calculated with the theoretical value and test value. 
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Fig. 10: Antigen binding capacity after the replacement of the human-derived Igκ 
constant region with a human-derived Igλ5 constant region. (A) ELISA analysis of 
NP antigen binding capacity of IGHV1-72 antibodies. (B) ELISA analysis of CGG 
antigen binding capacity of IGHV9-3 antibodies. Statistical significance was tested 
using Student’s t-test (*; P<0.05, n = 3). 
  
0.0  
0.5  
1.0  
1.5  
2.0  
2.5  
CGG 
0.0  
0.2  
0.4  
0.6  
0.8  
1.0  
1.2  
NP-BSA 
A B
N
P-
B
SA
 b
in
di
ng
 
(O
D
 4
50
nm
) 
NP-specific heavy chain  
  IGHV1-72 
		*
	*
C
G
G
 b
in
di
ng
 
(O
D
 4
50
nm
) 
CGG-specific heavy chain  
  IGHV9-3 
	* *
 89 
 
Fig. 11: Docking simulation results for human-derived Igκ  and Igλ5 constant 
region antibodies binding to NPA molecule. The results are shown as - docking 
scores (binding energy). 
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Fig. 12: Matching of different light chains and mouse-derived NP- and 
CGG-specific heavy chains. Western blot analysis was used for detecting the 
expression of recombinant antibodies. The heavy chain (top) and light chain (bottom) 
bands are shown. 
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Fig. 13: Prediction of binding pattern between receptors and ligand in silico. 
Evaluation of the crystal structure of NP-specific 1NGP antibody, and the structure of 
the antibody models containing NP-specific IGHV1-72 and three different light chains 
after refinement. The percentage of residues in most favoured, additional allowed, 
generously allowed and disallowed regions in Ramachandran Plot are shown. 
  
																	                                                                     Procheck 
                                          Evaluation of the stereo-chemical quality of a protein structure 
  
              Structure																															Core											Additional											Generously								Disallowed	
	
           1NGP                            85.5%         12.8%                1.1%              0.6% 
IGHV1-72Cγ/Mm_λ1Cκ                83.3%         14.8%                1.1%              0.8% 
IGHV1-72Cγ/Mm_VpreBλ5Cκ      80.7%         16.9%                 0.8%              1.6% 
IGHV1-72Cγ/Hs_VpreBλ5Cκ        80.7%         18.2%                 0.5%               0.5%
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Fig. 14: Interactions between NPA and different receptors. (a) Binding pose of 
crystallographic structure of 1NGP; (b) Optimal binding pose between NPA and 
IGHV1-72/Mm_λ1; (c) Binding pose for IGHV1-72/Mm_VpreBλ5; (d) Binding pose 
for IGHV1-72/Hs_VpreBλ5.  
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Fig. 15: The genetic organization of CGG-specific IgH repertoires. CGG-specific 
IgH repertoires covering multiple D genes: IGHV9-3/IGHD3-1IGHD4-1/IGHJ2. 
Heavy chain variable domain genes show that, CDR1 and CDR2 are encoded by V 
region; CDR3 is encoded by a part of V region and all of D and J regions. 
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Fig. 16: The examination of the antigen-binding sites in IGHV1-72 and IGHV9-3. 
(A) The antibody numbering of IGHV1-72/D1-1/J2 and IGHV9-3/D1-1/J2 by Kabat 
scheme and the point mutations from the original amino acid to Alanine. CDR1 and 
CDR2 were annotated in orange; CDR3 was annotated in red. The mutations were 
labeled upon the originals in blue. (B) The binding capacities between the originals and 
mutations were tested by ELISA. The error bar indicates standard deviations of three 
independent experiments performed in triplicates. Statistical significance was tested 
using Student’s t-test (*; P<0.05, n = 3). 
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Fig. 17: Binding capacity of different antibodies to NP-BSA and CGG antigen. The 
supernatants were diluted in wash buffer, and the antibody concentration was adjusted 
to 10 µg/mL. Then, the samples were added to microtiter wells containing coated 
antigens at three different concentrations diluted from 20 µg/mL. The error bar indicates 
standard deviations of three independent experiments performed in triplicates. 
Statistical significance was tested using Student’s t-test (*; P<0.05, n = 3). 
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Fig. 18: In silico simulation for analyzing the non-specific binding to NPA in the 
antibodies containing IGHV9-3 and VpreB1λ5Cκ light chains. The docking results 
were shown as binding energy, suggesting that IGHV9-3 pairing with Hs_VpreB1λ5Cκ 
increased the non-specific of NP binding. 
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Fig. 19: Comparison of antigen binding affinity of different antibodies depending 
on the antibody concentration. The antigen concentration was diluted to 5 µg/mL. 
Antibody binding was detected with the goat anti-human IgG, (H+L) HRP conjugate. 
The binding activities of the antibodies are expressed in terms of O.D. 450 nm. Error 
bars indicate standard deviations of the means in three independent experiments 
performed in triplicates. 
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Fig. 20: Phylogenetic tree for antigen-specific IgH repertoires. The tree was 
generated using the neighbor-joining (NJ) algorithm with the MEGA7 software. Red, 
NP-specific; Blue, CGG-specific. 
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Fig. 21: Western blot analysis for the expression of recombinant antibodies. Equal 
volumes of cell culture supernatants were subjected to 12% SDS-PAGE, and antibody 
expression was detected with HRP-conjugated anti-human IgG antibody for heavy 
chains and HRP-conjugated anti-human Igκ antibody for light chains. Heavy chain 
bands are at the top, and light chain bands are at the bottom. 
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Fig. 22: Binding capacity of the recombinant antibodies to NP-BSA and CGG 
antigens. The cutoff was determined by the mean value plus standard deviation of CHO 
cell culture medium. The error bar indicates standard deviations of three independent 
experiments performed in triplicate. 
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Fig. 23: IgHs derived from different clans. Different IgHs were chosen as samples for 
testing the binding capacity, including the mouse-derived IgH sequences from the 
reported structures (PDB ID): 1A3R, 5EOQ and 2HRP; the human-derived IgH 
sequences from the reported structures (PDB ID): 5ERW, 3MOD and 4XMK. 
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Fig. 24: Docking results of VpreB1λ5Cκ  antibody structures (docked ligand: 
Yellow; co-crystallized ligand: Blue). (A) Mouse-derived IgHs pairing with 
Mm_VpreB1λ5Cκ. (B) Human-derived IgHs pairing with Hs_VpreB1λ5Cκ. The 
RMSD values between the co-crystallized and the docked ligands were shown. 
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Fig. 25: The Plots for the binding energy after docking. The docking results of the 
original structures and VpreB1λ5Cκ structures are shown as - docking score (binding 
energy). The results of mouse-derived antibodies are on the top and those of 
human-derived antibodies are on the bottom. 
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Fig. 26: The RMSD plots for MD simulations of mouse-derived antigen-antibody 
complexes. 5 ns molecular dynamics simulation were performed. The light colors 
indicate the original structures and the deep color indicate the Mm_VpreB1λ5Cκ 
structures. 
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Fig. 27: The RMSD plots for MD simulations of human-derived antigen-antibody 
complexes. 10 ns molecular dynamics simulation were performed. The light colors 
indicate the original structures and the deep color indicate the Hs_VpreB1λ5Cκ 
structures. 
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Fig. 28: Calculation of free energy of binding. The trajectories from the stable 
structures were chosen for the calculation of free energy of binding. The results of 
mouse-derived antibodies are shown on the top and the human-derived antibodies are 
shown on the bottom. The error bar indicates standard deviations. 
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